Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — FY2019/20 Earnings Presentation
10 slides from Coloplast A/s Class B's earnings presentation, Nov 3, 2020
Slide 1: Coloplast Earnings Conference Call FY 2019/20
Sustainable growth leadership Coloplast Earnings Conference Call FY 2019/20 3 November 2020 Making life easier Ostomy Care, Continence Care, Wound & Skin Care and Interventional Urology
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Back to organic growth in Q4. Solid results for FY 2019/20 despite challenging year
Back to organic growth in Q4. Solid results for FY 2019/20 despite challenging year due to COVID-19 pandemic 2019/20 Highlights Revenue growth +4% • Organic growth of 4% and 3% reported growth in DKK Reported revenue (DKKm) • FY organic growth negatively impacted by COVID-19, particularly the +3% ca
Slide 4: Coloplast acquires Nine Continents Medical Inc, an early stage company in the over-active bladder segment
Coloplast acquires Nine Continents Medical Inc, an early stage company in the large over-active bladder segment Over-active bladder market Company and product description • Over-active bladder (OAB) is a condition that causes a frequent and • Nine Continents Medical Inc is an early stage company pio
Slide 5: All business areas adversely impacted by COVID-19 in 2019/20 in particular Interventional Urology
All business areas adversely impacted by COVID-19 in 2019/20 in particular Interventional Urology FY 19/20 revenue by business area FY 19/20 revenue by geography Business Reported revenue Organic growth Geographic Reported revenue Organic growth Share of organic area DKKm area DKKm growth Ostomy Car
Slide 6: FY 2019/20 revenue growth adversely impacted by COVID-19 and depreciation of emerging market currencies
FY 2019/20 revenue growth adversely impacted by COVID- 19 and depreciation of emerging market currencies Comments Revenue development • FY 2019/20 reported revenue increased by DKK 605m (DKKm) or 3% compared to FY 2018/19 737 • The majority of growth was driven by organic growth 18,544 contributing
Slide 7: EBIT margin of 32% in 2019/20 driven by prudent cost management and lower travel & marketing spend
EBIT margin of 32% in 2019/20 driven by prudent cost management and lower travel & marketing spend Comments EBIT margin development (%) • FY 19/20 gross margin of 68% in DKK on par with last year 0.1 0.0 -0.2 • Positive impact from GOP4 and the closure of the Thisted factory in 0.4 June 2019 31.6 •
Slide 8: FCF driven by solid underlying development in earnings
FCF driven by solid underlying development in earnings FCF development Comments • Free cash flow in FY 2019/20 was DKK 3,858m, up 2% compared to DKK 3,766 in FY 2018/19 not adjusting for mesh payments 98 99 98 • Adjusted for the positive impact of DKK 197m related to the 92 93 90 reclassification of
Slide 9: Financial guidance for FY 2020/21
Financial guidance for FY 2020/21 Guidance 2020/21 Guidance 2020/21 (DKK)* Key assumptions • Phasing of growth expected to be back-end loaded with low single- digit growth in H1 and double-digit growth in H2 7-8% • Interventional Urology positively impacted by comparison period in 2019/20 Sales grow
Slide 10: Our mission, values and vision
Our mission Making life easier for people with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | us Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /